14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ZJYL vs FEMY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, JIN MEDICAL INTERNATIONAL LTD. (ZJYL) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZJYL carries a Unified Composite Score of 33.1/100 (SELL) at $3.63 (N/M Forward P/E, 2.1% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin).
Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. ZJYL 33.1/100 SELL), ZJYL captures the overall institutional head-to-head verdict (7–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (2.1% vs. -763.9% operating margin) and revenue trajectory (-9.7% vs. -18.9% YoY).
Technical & Structure Timing Caution: ZJYL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.7); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZJYL vs FEMY. Trailing 12-month operating profitability (ZJYL 2.1% vs FEMY -763.9%) and valuation multiples (ZJYL N/M vs FEMY N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ZJYL vs FEMY Key Questions & Quantitative Answers
As of Nov 16, 2026, JIN MEDICAL INTERNATIONAL LTD. (ZJYL) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZJYL carries a Unified Composite Score of 33.1/100 (SELL) at $3.63 (N/M Forward P/E, 2.1% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. ZJYL 33.1/100 SELL), ZJYL captures the overall institutional head-to-head verdict (7–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (2.1% vs. -763.9% operating margin) and revenue trajectory (-9.7% vs. -18.9% YoY). Technical & Structure Timing Caution: ZJYL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.7); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ZJYL leads the Growth & Scale pillar: ZJYL posts -9.7% YoY revenue growth and -32.0% YoY earnings growth on $508M TTM revenue (31.3% gross margin, 2.1% operating margin), compared with FEMY at -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin). On trailing 12-month operating scale, ZJYL generates $508M in USD-normalized revenue versus $2.3M for FEMY. In operating R&D and SG&A reinvestment, ZJYL deploys 29.2% of Rev ($148M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FEMY.
ZJYL screens cheaper on headline valuation multiples. ZJYL trades at N/M Forward P/E, 18.4x Trailing P/E, N/M PEG, and 1.1x EV/Revenue (3.3% EBITDA margin), whereas FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZJYL (4.0% ROE) versus FEMY (-425.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ZJYL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (14.10β · 180% Vol realized risk). By comparison, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.